奥沙利铂片联合替吉奥胶囊治疗中晚期胃癌的远期临床疗效研究

Clinical trial of oxaliplatin tablets combined tegafur,gimeracil and oteracil porassium capsules on long-term efficacy in the treatment of advanced gastric cancer

目的观察奥沙利铂联合替吉奥或替加氟治疗中晚期胃癌的远期临床疗效。方法将50例中晚期胃癌患者随机分为试验组25例和对照组25例。试验组患者给予奥沙利铂130 mg·m^(-2)加入5%葡萄糖注射液500 m L,静脉滴注90 min,第1天;替吉奥40~60 mg·m^(-2),每天2次,第1~14天,休息7 d,21 d为一个周期。对照组患者给予奥沙利铂130 mg·m^(-2)加入5%葡萄糖注射液500 m L,静脉滴注90 min,第1天;替加氟1 g,第1~5天,缓慢静脉注射。有效者给予4个以上周期化疗,直至出现不可耐受毒性。每位患者至少给予2个周期化疗。比较2组患者的近期疗效、远期生存率和药物不良反应发生情况。结果试验组和对照组患者得临床治疗有效率分别为92.0%,64.0%,组间比较差异有统计学意义(P<0.05)。试验组患者短期治疗效果显著优于对照组患者,差异有统计学意义(P<0.05)。试验组的药物不良反应发生率为28%,显著低于对照组患者的96%,差异有统计学意义(P<0.05)。结论奥沙利铂联合替吉奥治疗中晚期胃癌的临床疗效显著优于奥沙利铂联合替加氟,且前者药物不良反应的发生率也显著低于后者。

Objective To investigate the long - term efficacy of oxali- platin tablets combined tegafur,gimeracil and oteracil porassium capsules or tegafur in the treatment of advanced gastric cancer. Methods Fifty cases of patients with advanced gastric cancer were randomly divided into two groups, 25 cases in each group. Treatment group was treated with oxali- platin 130 mg m-2, adding 5% glucose injection 500 mL, the first day of intravenous infusion of 90 min; tegafur, gimeracil and oteracil porassi- um capsules 40 - 60 mg m-2, two times a day, from first to fourteenth, 7 days of rest, 21 days a course of treatment. Patients in the control group were treated with oxaliplatin 130 mg m -2, adding 5% glucose in- jection 500 mL, the first day of intravenous infusion of 90 min ; the first day of the tegafur 1 g, from first to fifth, slow intravenous injection. Each patient was given at least two cycles of chemotherapy, which was given more than four cycles of chemotherapy until the emergence of an intolerance. The short- term efficacy, long- term survival rates and adverse drug reaction （ADR）of the two groups were compared. Results The clinical efficacy rate in treatment and control groups were 92. 0%, 64. 0%, the difference had significantly（P 〈0. 05）. The short -term therapeutic effect of treatment group was significantly better than that of control group （P 〈0. 05）. The ADR of patients in treatment group was 28% significantly lower than 96% in control group （P 〈0. 05）. Conclusion The oxaliplatin combined with tegafur, gimeracil and oteracil porassium capsules was used in the treatment of advanced gastric cancer, there was excellent clinical results, good safety.